RxDoctor Payments Data

Mohammad Ibrahim, DO

Family Medicine · Montgomery, ALNPI 1295081198

Payments from drug & device makers

$333in general payments, 2019–2025

Across 17 payments — averaging $19.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$80
  • Intuitive Surgical$45
  • Novartis$44
  • AbbVie$38
  • Pfizer$38
  • Amgen$24
  • plus $65 from 4 others

What the payments were for

  • Food & beverage$333100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson(2 entities)4$80
Intuitive Surgical1$45
Novartis2$44
AbbVie2$38
Pfizer2$38
Amgen1$24
Lilly USA, LLC2$23
Novo Nordisk1$15
GSK1$13
AstraZeneca1$12

How this compares

$333 in reported general payments places this provider in the 35th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$118,226
Medicare patients
384
Services billed
1,498

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate89$85,300
EliquisApixaban107$75,031
OzempicSemaglutide52$57,769
MounjaroTirzepatide43$53,736
TrulicityDulaglutide29$33,790
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$29,386
EntrestoSacubitril/Valsartan25$26,677
XareltoRivaroxaban20$22,016
LinzessLinaclotide28$21,600
FarxigaDapagliflozin Propanediol26$21,000
JanumetSitagliptin Phos/Metformin Hcl12$17,784
SymbicortBudesonide/Formoterol Fumarate38$11,503
Lantus SolostarInsulin Glargine,hum.Rec.Anlog69$10,287
Spiriva HandihalerTiotropium Bromide17$8,724
MyrbetriqMirabegron13$8,252

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$23$87,52672 claims
PfizerEliquis$38$75,031107 claims
Novo NordiskOzempic$15$57,76952 claims
GSKTrelegy Ellipta, Breo Ellipta$13$34,17854 claims
AstraZenecaFarxiga, Symbicort$12$32,50364 claims
NovartisEntresto$44$26,67725 claims
Johnson & JohnsonXarelto$80$22,01620 claims
AbbVieLinzess$38$21,60028 claims
AmgenCorlanor$24$6,13611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Montgomery

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →